| Acute Leukemia |
1 |
1 |
| Stem Cell Research and Therapy |
0 |
0.55 |
| Risk Evaluation and Mitigation Strategies |
0 |
0.54 |
| Patient Safety |
0 |
0.52 |
| Revenue and Practice Management |
0 |
0.52 |
| Tyrosine Kinase Inhibitor |
0 |
0.51 |
| Tyrosine Kinase |
0 |
0.43 |
| Neutropenia |
0 |
0.42 |
| Biologic Therapy |
0 |
0.38 |
| Chemotherapy |
0 |
0.29 |
| Hypokalemia |
0 |
0.29 |
| Acute Myeloblastic Leukemia |
0 |
0.99 |
| Cell Transplantation |
0 |
0.2 |
| Anthracyclines |
0 |
0.14 |
| Arrhythmia |
0 |
0.14 |
| Cardiac Arrest |
0 |
0.14 |
| Diarrhea |
0 |
0.14 |
| Genetics |
0 |
0.14 |
| Genomic Medicine |
0 |
0.14 |
| Grant |
0 |
0.14 |
| Hypoalbuminemia |
0 |
0.14 |
| Hypocalcemia |
0 |
0.14 |
| Hypomagnesemia |
0 |
0.14 |
| Hypophosphatemia |
0 |
0.14 |
| Leukemia |
0 |
0.14 |
| Mucositis |
0 |
0.14 |
| Nausea |
0 |
0.14 |
| Pneumonia |
0 |
0.14 |
| Receptors |
0 |
0.14 |
| Torsades de Pointes |
0 |
0.14 |
| Transplantation |
0 |
0.14 |
| Tumor |
0 |
0.14 |